The perspective highlights Rwanda’s remarkable response to the 2024 Marburg virus disease (MVD) outbreak, emphasizing high-quality care, genomic surveillance, and collaborative trials as key factors in achieving an unprecedented 77% survival rate. It positions Rwanda’s approach as a model for integrating equity and clinical excellence in epidemic management.
While the perspective celebrates Rwanda’s success, the discussion on the role of genomic analysis in contact tracing and outbreak control is brief and lacks specific data. Could the authors elaborate on how genomic findings influenced public health interventions, such as isolating cases or targeting high-risk groups?
Moreover, the survival rate comparison with previous outbreaks assumes equivalence in baseline patient characteristics and viral dynamics. Were adjustments made to account for these differences, or could these factors partly explain the lower case fatality rate?